Research and Markets (http://www.researchandmarkets.com/research/vkgvkn/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H2 2013" report to their offering.

'Chronic Urticaria Or Hives - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline.

This report provides information on the therapeutic development for Chronic Urticaria Or Hives, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives.

Companies Mentioned

  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Merck & Co., Inc.
  • Biofrontera AG
  • Sun Pharmaceutical Industries Limited
  • FAES Farma SA
  • AEterna Zentaris Inc.
  • JDP Therapeutics Inc.

Scope

  • A snapshot of the global therapeutic scenario for Chronic Urticaria Or Hives.
  • A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Chronic Urticaria Or Hives pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

For more information visit http://www.researchandmarkets.com/research/vkgvkn/chronic_urticaria

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals